Showing posts with label Launches. Show all posts
Showing posts with label Launches. Show all posts

Friday, December 10, 2010

The NHS Technology Adoption Centre Launches Guide To Redress The Major Inequities Which Exist In The Provision Of Diabetes Treatment


Main Category: Diabetes
Article Date: 26 Nov 2010 - 1:00 PST window.fbAsyncInit = function() { FB.init({ appId: 'aa16a4bf93f23f07eb33109d5f1134d3', status: true, cookie: true, xfbml: true, channelUrl: 'http://www.medicalnewstoday.com/scripts/facebooklike.html'}); }; (function() { var e = document.createElement('script'); e.async = true; e.src = document.location.protocol + '//connect.facebook.net/en_US/all.js'; document.getElementById('fb-root').appendChild(e); }()); email icon email to a friend ? printer icon printer friendly ? write icon opinions ?
not yet ratednot yet rated
The NHS Technology Adoption Centre has launched the How To Why To Guide on Insulin Pump Therapy and believes that this tool can help redress the inequities which currently exist in the treatment of type 1 diabetes. The Guide, which is the result of an intensive two-year project, provides practice guidance to enable the successful implementation of the therapy. The unique tool provides:

- clinical evidence enabling hospitals to better understand insulin pump therapy;
- support to put together a business case which guides the commissioning process;
- a roadmap to pump service implementation and the necessary supporting policies.

Commenting on the Guide, Dr Rowan Hillson MBE, National Clinical Director for Diabetes said: "People with diabetes should have access to the most appropriate insulin therapy for their needs. This includes insulin pumps where they are indicated. I believe that the How To Why To Guide will be a valuable tool to facilitate the wider adoption of insulin pump therapy and I encourage people to use it in their clinical settings."

Three NHS Trusts have been involved in the development of the Guide; each having successfully implemented an insulin pump therapy service.

- Birmingham Children's Hospital NHS Foundation Trust
- Whittington Hospital NHS Trust
- East Lancashire Hospitals NHS Trust

It is estimated that, in the UK, 1 in 200 adults have type 1 diabetes with the current prevalence in children approximately 1 in 700-1000.

In order to avoid complications it is important that those with type 1 diabetes manage their blood glucose levels carefully. An internationally accepted measure of good diabetes control is the glycated haemoglobin (HbA1c). The NICE guidance for diabetes care and the Quality and Outcomes Framework advocate a treatment target of HbA1c < 7.5%. However, the National Diabetes Audit has recently shown that 85% of children with diabetes do not meet this target putting them at substantially greater risk of complications.

The majority of patients control their insulin levels through multiple daily injections (MDI). However, in many cases this leads to poor control of diabetes and can also negatively affect an individual's quality of life.

An alternative to MDI is insulin pump therapy. This portable pump provides precise dosing of insulin with controlled and steady delivery controlling the infusion of insulin in a more flexible manner than conventional insulin injections. NICE recommends the use of insulin pump therapy for some people with type 1 diabetes and estimates that it is likely to benefit 8-15 per cent of adults and up to 50 per cent of children under the age of 12.

However, despite positive NICE guidance insulin pump therapy is poor with considerable inequities in both provision and access being found across the UK with many areas having less than 1 percent take up. The UK also significantly lags behind many other parts of the world where, in some countries, uptake is nearing 40 percent.

In order to overcome these issues NTAC developed the How To Why To Guide on Insulin Pump Therapy. The IPT Guide is one of a series designed to address the issues of poor technology adoption across the NHS.

Source:
NHS Technology Adoption Centre

Please rate this article:
(Hover over the stars
then click to rate) Bookmark and Share

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.

All opinions are moderated before being added.

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:






View the original article here

Monday, November 29, 2010

Press Release - Bristol-Myers Squibb Foundation Launches $100 Million Initiative Targeting America's Type 2 Diabetes Crisis

Bristol-Myers Squibb Foundation Launches $100 Million Initiative Targeting America's Type 2 Diabetes Crisis - Diabetes Health Diabetes Health - Your Essential Diabetes News Sourcewdd-top My Account ??|??Subscribe??|??Contact Us??|??Donate Search Home Home Charts Recipes Digital Edition TV Apps Community Kids & Teens Type 2 Issues Type 1 Issues Professional Issues Pre-Diabetes Beginners International Health Events History Camps for Kids Online Resources Dating World Diabetes Day Pets All Sections Products Product Directory Charts Syringes Insulin Pumps Meters Pens Software CGMs Books Medical ID Jewelry Lancing Devices Infusion Sets Carrying Cases Pen Needles All Sections Complications & Care Heart Care & Heart Disease Low Blood Sugar Foot Care Kidney Care (Nephropathy) Nerve Care (Neuropathy) Eye Care (Retinopathy) Hypoglycemia Unawareness Sexual Issues Geriatrics Depression Insulin Resistance Skin Care Lipid Problems Wound Care Reversing Complications All Sections Food Recipes Diets Vitamins Food News Nutrition Advice Low Carb Supplements Glycemic Index & Carb Counting Beverages Low Calorie & Low Fat Sugar & Sweeteners Desserts Herbs Dinner Lunch All Sections Columns Cartoons & eCards Personal Stories Letters to the Editor Inspiration My Own Injection Book Reviews Motivation Heroes Making a Difference CDE of the Month Doctors & Nurses Love and Diabetes After All These Years All Sections Medications Insulin Type 2 Medications Metformin Pharmacy Lantus Byetta Actos Animal Insulin Januvia Victoza Symlin Apidra Onglyza Voglibose All Sections Research Nutrition Research Islet & Pancreas Transplant Medications Research Health Research The Cure Beta Cells Other Lab Tests Artificial Pancreas New Cure Research Case Studies All Sections Fitness Exercise Weight Loss Bariatric Surgery Success Stories Amphetamines All Sections Psychology Adolescent Boys Adolescent Girls Living with Diabetes Support Groups Women's Issues Men's Issues Teenagers Insulin Omission All Sections Monitoring Blood Sugar A1c Test Noninvasive Monitors Urine Test Laboratory Tests All Sections Health Care Health Insurance Hospital Care Endocrinology Complementary Therapies Smoking CDE Physical Therapy All Sections Legal Government & Policy Discrimination Drivers License & Pilot License Politics Driving 504 Plan in School Lobbying All Sections Pregnancy Childbirth Breastfeeding Gestational Diabetes All Sections Celebrities Nick Jonas Jay Hewitt Scott Dunton Elliott Yamin All Sections About UsAbout UsPublisher's LetterAdvertisingContact UsPress RoomSubmission GuidelinesPrivacy Policy Help function fbs_click() {u=location.href;t=document.title;window.open('http://www.facebook.com/sharer.php?u='+encodeURIComponent(u)+'&t='+encodeURIComponent(t),'sharer','toolbar=0,status=0,width=626,height=436');return false;} Diabetes Health magazine
Click to Read FreeDiabetes Health magazine
Click to SubscribeSee What's Inside… Living His Dream of Law Enforcement: Lt. Jose Lopez Diabetes & Alcohol Diabetes and Autoimmunity Insulindependence Precious Pooch See the entire table of contents here!

View Diabetes Health Magazine For Free Online

You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To ViewFree Subscription to Diabetes Health Professional

If you are a physician, educator and medical professional who focus on the treatment of diabetes, then this is the must have resource for you.

Finally! A fresh take on the “professional” journal. Each bi-monthly issue cuts through the jargon and presents the most important information you need to enhance your practice and assist your patients.

Each bi-monthly issue of Diabetes Health Professional is a self-contained handbook covering products, educational resources and the latest diabetes research, complimented by balanced editorial focused on medical news, drug prescription information, clinical practice recommendations and changing treatment options.

Each quarter we send you the latest, most updated research guides, product guides and educational resource guides available for you and your patients.

Learn More About the Professional Subscription

Diabetes Health E-Newsletter

Each week the Diabetes Health E-Newsletter delivers links to the very latest in news, reviews, blogs and videos from Diabetes Health direct to your inbox.

See an example E-Newsletter

As a subscriber you'll get access to the amazing Diabetes Health Digital Advantage™ so you can read the current issue of Diabetes Health magazine online wherever you are!

Email Address: Area of Interest: Consumer Professional How To Change Your Newsletter Email…

You can cancel your newsletter subscription at anytime by clicking "Unsubscribe" on the bottom of any newsletter you receive

Then enter your new email address in the above form and click "Subscribe"

wdd-ros LatestPopularTop RatedLatest Community Articles

Diabetes Association of Atlanta Caps Off Successful Diabetes UniversityHandle online advice with careBristol-Myers Squibb Foundation Launches $100 Million Initiative Targeting America's Type 2 Diabetes CrisisBe Part of the CureThis World Diabetes Day, Measure Your Risk of Type 2 DiabetesDiabetes Month: Get Involved!Solianis Working on Noninvasive Continuous Glucose Monitoring for Patients With DiabetesBring Diabetes To Light! JDRF Clinical Panel Recommends Next Steps for Artificial Pancreas Clinical Testing Is Correcting Low Blood Sugars Caused by Exercise Making You Fat?Popular Community Articles

Type 1 Pop Star, Nick Jonas Tells His StoryLantus and Levemir: What's the Difference?Bret Michaels, Diabetic Lead Singer of PoisonThe History of DiabetesLegal and Illegal Drugs: What Every Person With Diabetes Should Know Before They PartyCinnamon: Should It Be Taken as a Diabetes Medication?Why Eating Too Many Carbs Makes You FatLow Carbohydrate Diets: Why You Don't Want the "Experts" to Tell You What to EatScrawny Boy With Type 1 Diabetes Becomes Mr. UniverseInsulin For Type 2 Diabetes: Who, When, And Why?Highly Recommended Community Articles

Type 1 Pop Star, Nick Jonas Tells His StoryJonas Brothers Band Member Reveals He Has Diabetes: Nick Jonas, age 14, hopes his story will inspire other kids with diabetesJonas Brothers Update: Diabetes Has Not Slowed Down 15-Year-Old Nick JonasWoman Loses 134 Pounds in One YearLow Carbohydrate Diets: Why You Don't Want the "Experts" to Tell You What to EatBret Michaels, Diabetic Lead Singer of PoisonInsulin For Type 2 Diabetes: Who, When, And Why?Has Anyone Else Reversed Diabetes Complications? If You Have, I Want to Hear From You!Mr. Universe Assaulted by Police During Low Blood Sugar EpisodeScrawny Boy With Type 1 Diabetes Becomes Mr. UniverseCommunity ArchivesBrowse the Community ArchivesSubscribe to the Community RSS Feed Print|Email|Share|Comments (1)Email to a Friend

Send a link to this page to your friends and colleagues.

Your Name:Your Email:Recipient's Name:Recipient's Email:CloseBristol-Myers Squibb Foundation Launches $100 Million Initiative Targeting America's Type 2 Diabetes CrisisNov 15, 2010 This press release is an announcement submitted by Bristol-Myers Squibb Foundation , and was not written by Diabetes Health.

The?Bristol-Myers Squibb Foundation announced Together on Diabetes®: Communities Uniting to Meet America's Diabetes Challenge,?a 5-year, $100 million initiative to help patients living with type 2 diabetes better manage their disease beyond the doors of their doctor's office - in their homes and communities - and for the course of their disease.

The largest corporate philanthropic commitment to fighting type 2 diabetes in the United States,?Together on Diabetes®?will draw upon the Foundation's deep experience supporting community-based, non-medical support services that complement medical care and improve health outcomes. This approach - first employed by the Foundation in 1999 as part of its groundbreaking $150 million?SECURE THE FUTURE®?initiative to fight HIV/AIDS in Africa - helps remove barriers to diagnosis and care while empowering patients to understand their role in managing their disease and reducing the risks it can pose to their health.

Together on Diabetes®?is the Foundation's first large-scale diabetes initiative. Working with a wide variety of community-based, regional and national partners,?Together on Diabetes®?will support efforts to develop and expand effective patient self-management programs and broadly engage affected communities in the fight against type 2 diabetes. The initiative's "innovation fund" will encourage and test new ideas for controlling type 2 diabetes, which today affects about one in 12 Americans and could affect as many as one in three Americans by 2050.?Together on Diabetes®?also released its first request for proposals, which focuses on African American women.

"Type 2 diabetes is one of the United States' greatest health challenges and disproportionately affects the poor, minorities and the elderly, many of whom are not receiving the care and support they need to improve their glycemic control," says Lamberto Andreotti, chief executive officer, Bristol-Myers Squibb. "Together on Diabetes®?will draw on the strengths of communities and support public- and private-sector partners coming together to identify and implement disease management approaches that work for large segments of the population."

The U.S. Centers for Disease Control and Prevention (CDC) reports that 57 million Americans are pre-diabetic and at increased risk of developing type 2 diabetes in the next 10 years. About 1.6 million new cases of diabetes are diagnosed in people age 20 and older each year. African Americans, Hispanics, Native Americans and Asian Americans, including Native Hawaiians and other Pacific Islanders, and the elderly, are more likely to develop type 2 diabetes than non-Hispanic whites.

"This initiative harnesses the strength of corporate philanthropy and non-profit sector expertise to enhance type 2 diabetes awareness in the most at risk and affected communities," said Deborah Fillman, M.S., R.D., L.D., C.D.E., president of the American Association of Diabetes Educators. "We believe it will yield clear and measurable results and reduce the scope of the type 2 diabetes epidemic in the U.S."

The human and economic costs of uncontrolled diabetes are staggering and the need to step up control efforts is urgent. Nearly half of all patients diagnosed with type 2 diabetes - 48.3 percent - do not have their disease adequately controlled through a combination of diet, physical activity and medication. Patients with uncontrolled type 2 diabetes face increased risk of complications such as cardiovascular disease, high blood pressure and stroke; damage to the nerves, eyes and kidneys; and amputation of the fingers, toes or limbs. CDC estimates the U.S. spent $116 billion in 2007 for direct medical services to treat diagnosed cases of diabetes and $58 billion in indirect costs such as disability and lost work time.

"The health implications of type 2 diabetes are significant, both for the individual and for society," says John Damonti, president, Bristol-Myers Squibb Foundation, and vice president, Corporate Philanthropy, Bristol-Myers Squibb. "Our experiences with SECURE THE FUTURE®?and other Foundation initiatives around the world have shown that mobilizing affected communities can have a profound impact on improving patient quality of life and health outcomes."

The Foundation will make grants and forge partnerships through two processes: ongoing, opportunistic grantmaking and themed requests for proposals, which will be issued each November during National Diabetes Month. The initial grantees for Together on Diabetes®?are:

The American Academy of Family Physicians Foundation, in partnership with Peers for Progress, National Council of La Raza and the University of North Carolina's Gillings School of Global Public Health, will incorporate patient self-management education, peer support and community outreach for low-income Hispanics and African Americans into the patient-centered medical home model.The American Association of Diabetes Educators will conduct a pilot study of the effectiveness and sustainability of a flexible, multi-level diabetes education and support team that serves minority populations and that utilizes professional and lay health workers.The American Pharmacists Association Foundation, working with government agencies, professional associations, pharmacy chains and others, will adapt and expand the evidence-based Asheville Project model to patients covered by public and private health insurance in 25 communities heavily affected by diabetes. In this model, patients receive diabetes education and then are teamed with community-based pharmacists who make sure they use their medications correctly.The United Hospital Fund, working with the New York City Department of Health and Mental Hygiene and the Department for the Aging, will develop and test an integrated, community-based diabetes control strategy for seniors living in "naturally occurring retirement communities" and the surrounding neighborhoods.

Foundation seeks additional proposals

Together on Diabetes®?first request for proposals focuses on African American women. Five grants up to $300,000 each will be awarded. African American women represent one of the highest risk groups for type 2 diabetes based on prevalence and disease burden. About one in 10 African American women age 20 and older has diabetes, a rate that more than doubles to one in four for African American women over 55. African Americans also suffer high rates of diabetes' most serious complications: blindness, amputation and kidney failure. The purpose of the request for proposals is to encourage, identify and promote new evidence-based approaches to empowering African American women to control their diabetes while taking into account the opportunity they have to influence the health of their families and communities as well.

You can learn more about?Together on Diabetes®?at?TogetherOnDiabetes.com.

About the Bristol-Myers Squibb Foundation

The Bristol-Myers Squibb Foundation is an independent 501(c)(3) charitable organization whose mission is to reduce health disparities and improve health outcomes around the world for patients disproportionately affected by serious disease.

?

Categories: Community, Pre-Diabetes, Type 2 Issues

Share on Facebook Facebook Post to MySpace MySpace Digg! Digg Donate to Diabetes Health Recommend this :Not at allSomewhatModeratelyHighlyVery Highly
Average Rating:

You May Also Be Interested In...Click Here To View Or Post Comments Comment1 comment - Nov 15, 2010-*****

Home | Charts | Forums | Digital Edition | TV | Subscribe | Contact Us | Donate | Sitemapⓒ1991-2010 Diabetes Health

View the original article here

Friday, November 26, 2010

Two Reasons, One Recipe Campaign Launches To Educate Adults With Type 2 Diabetes And High Cholesterol About Healthy Food Choices


Main Category: Diabetes
Also Included In: Nutrition / Diet;??Cholesterol
Article Date: 17 Nov 2010 - 7:00 PST window.fbAsyncInit = function() { FB.init({ appId: 'aa16a4bf93f23f07eb33109d5f1134d3', status: true, cookie: true, xfbml: true, channelUrl: 'http://www.medicalnewstoday.com/scripts/facebooklike.html'}); }; (function() { var e = document.createElement('script'); e.async = true; e.src = document.location.protocol + '//connect.facebook.net/en_US/all.js'; document.getElementById('fb-root').appendChild(e); }()); email icon email to a friend ? printer icon printer friendly ? write icon opinions ?
1 starnot yet rated
The "Two Reasons, One Recipe" campaign is launching to focus attention on the importance of reducing A1C (blood sugar) and LDL-C ("bad" cholesterol) in adults with type 2 diabetes and high cholesterol, two important risk factors for cardiovascular disease.* In fact, more than 50 percent of adults with type 2 diabetes also have high LDL cholesterol.(1)

Franklin Becker, acclaimed Executive Chef of Abe & Arthur's restaurant in New York City, and Dr. Yehuda Handelsman, Medical Director of the Metabolic Institute of America in Tarzana, Calif., have teamed up with Daiichi Sankyo, Inc., to educate adults who have type 2 diabetes and high LDL cholesterol about making healthy food choices. Diagnosed with type 2 diabetes at age 27, Chef Becker is committed to creating healthy and flavorful recipes for people to create at home, and helping them to make appropriate choices when they are eating out.

"For the millions of American adults with type 2 diabetes and/or high LDL-C, trying to understand what you can and cannot eat may seem like an overwhelming burden. As part of the 'Two Reasons, One Recipe' campaign, I've developed a number of great new recipes that are flavorful and healthy for people with either or both of these chronic health conditions," said Chef Becker. "After being diagnosed with type 2 diabetes and seeing other family members also struggle with this condition, I made adjustments to my cooking style. I've incorporated these changes into my recipes, which I look forward to sharing with others across the country who, like me, want and need to eat healthier food."

The "Two Reasons, One Recipe" campaign features an online educational resource, www.TwoReasonsOneRecipe.com, where adults with type 2 diabetes and/or high LDL-C can find Chef Becker's recipes, cooking and shopping tips, and helpful information about type 2 diabetes and high LDL cholesterol. The campaign is supported by Daiichi Sankyo, Inc., the marketer of Welchol® (colesevelam HCl), and is launching in November 2010, which is recognized around the world as Diabetes Awareness Month.

"For many of my adult patients with type 2 diabetes and elevated LDL-C, managing their diet is one of the greatest challenges they face on a daily basis, which is why I'm excited to be partnering with Chef Franklin Becker on the 'Two Reasons, One Recipe' campaign," said Yehuda Handelsman, MD, FACP, FACE, FNLA Medical Director of the Metabolic Institute of America in Tarzana, Calif. "In my experience, the best approach to help adult patients with type 2 diabetes and elevated LDL-C effectively manage their conditions is one that's comprehensive and includes the right balance of diet, exercise and medications, such as Welchol. Welchol is currently the only product approved by the FDA (U.S. Food and Drug Administration), in addition to diet and exercise, to lower both A1C and LDL-C in adults with type 2 diabetes and high cholesterol.** Ask your healthcare provider if Welchol is right for you."

According to the American Diabetes Association (ADA), about 23.6 million, or 8 percent of people in the United States, have diabetes, and every 21 seconds another person is diagnosed.(2,3) Approximately 90 to 95 percent of those diagnosed with diabetes have type 2 diabetes.(2) The ADA and the American College of Cardiology emphasize that it is critical to reduce both A1C and LDL-C levels, as more than 50 percent of adults with type 2 diabetes also have elevated LDL-C, greatly increasing their risk of cardiovascular disease.*(1,4,5) The ADA recommends that in general, adult patients with type 2 diabetes target an A1C level of less than 7 percent, and an LDL-C goal of less than 100 mg/dL.(6)

Welchol has not been shown to prevent heart disease or heart attacks.

Welchol should not be used to treat type 1 diabetes or a condition known as ketoacidosis. Welchol has not been studied as a single medicine for T2DM or in combination with all anti-diabetes medications. Welchol is not for everyone, especially those with a history of intestinal blockage, those with blood triglyceride levels of greater than 500 mg/dL, or a history of pancreatitis (inflammation of the pancreas) due to high triglyceride levels.

IMPORTANT INFORMATION ABOUT WELCHOL

Indications

Welchol is indicated as an adjunct to diet and exercise to:

-- reduce elevated low-density lipoprotein cholesterol (LDL-C) in patients with primary hyperlipidemia (Fredrickson Type IIa) as monotherapy or in combination with an hydroxymethylglutaryl-coenzyme (HMG CoA) reductase inhibitor (statin)

-- reduce LDL-C levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia, as monotherapy or in combination with a statin after failing an adequate trial of diet therapy

-- improve glycemic control in adults with type 2 diabetes mellitus

Important Limitations of Use

-- Welchol (colesevelam HCl) should not be used for the treatment of type 1 diabetes or for the treatment of diabetic ketoacidosis

-- Welchol has not been studied in type 2 diabetes as monotherapy or in combination with a dipeptidyl peptidase 4 inhibitor and has not been extensively studied in combination with thiazolidinediones

-- Welchol has not been studied in Fredrickson Type I, III, IV, and V dyslipidemias

-- Welchol has not been studied in children younger than 10 years of age or in premenarchal girls

Contraindications

Welchol is contraindicated in individuals with a history of bowel obstruction, those with serum triglyceride (TG) concentrations of >500 mg/dL, or with a history of hypertriglyceridemia-induced pancreatitis.

Warnings and Precautions

The effect of Welchol on cardiovascular morbidity and mortality has not been determined.

Welchol can increase serum TG concentrations particularly when used in combination with sulfonylureas or insulin. Caution should be exercised when treating patients with TG levels >300 mg/dL.

Welchol may decrease the absorption of fat-soluble vitamins A, D, E, and K. Patients on vitamin supplements should take their vitamins at least 4 hours prior to Welchol. Caution should be exercised when treating patients with a susceptibility to vitamin K or fat-soluble vitamin deficiencies. Caution should also be exercised when treating patients with gastroparesis, gastrointestinal motility disorders, a history of major gastrointestinal tract surgery, and when treating patients with dysphagia and swallowing disorders.

Welchol reduces gastrointestinal absorption of some drugs. Drugs with a known interaction with colesevelam (cyclosporine, glyburide, levothyroxine, and oral contraceptives [ethinyl estradiol, norethindrone]), should be administered at least 4 hours prior to Welchol. Drugs that have not been tested for interaction with colesevelam, especially those with a narrow therapeutic index, should also be administered at least 4 hours prior to Welchol. Alternatively, the physician should monitor drug levels of the co-administered drug.

To avoid esophageal distress, Welchol for Oral Suspension should not be taken in its dry form.

Due to tablet size, Welchol for Oral Suspension is recommended for, but not limited to, use in the pediatric population as well as in any patient who has difficulty swallowing tablets.

Phenylketonurics: Welchol for Oral Suspension contains 48 mg phenylalanine per 3.75 gram dose.

Adverse Reactions

In clinical trials, the adverse reactions observed in ≥2% of patients, and more commonly with Welchol than placebo, regardless of investigator assessment of causality seen in:

-- Adults with Primary Hyperlipidemia were: constipation (11.0% vs 7.0%), dyspepsia (8.3% vs 3.5%), nausea (4.2% vs 3.9%), accidental injury (3.7% vs 2.7%), asthenia (3.6% vs 1.9%), pharyngitis (3.2% vs 1.9%), flu syndrome (3.2% vs 3.1%), rhinitis (3.2% vs 3.1%), and myalgia (2.1% vs 0.4%)

-- Pediatric patients with heFH primary hyperlipidemia were: nasopharyngitis (6.2% vs 4.6%), headache (3.9 vs 3.1%), fatigue (3.9% vs 1.5%), creatine phosphokinase increase (2.3% vs 0.0%), rhinitis (2.3% vs 0.0%), and vomiting (2.3% vs 1.5%)

-- Adult patients with Type 2 Diabetes were: constipation (8.7% vs 2.0%), nasopharyngitis (4.1% vs 3.6%), dyspepsia (3.9% vs 1.4%), hypoglycemia (3.0% vs 2.3%), nausea (3.0% vs 1.4%), and hypertension (2.8% vs 1.6%)

Post-marketing experience: Due to the voluntary nature of these reports it is not possible to reliably estimate frequency or establish a causal relationship:

-- Increased seizure activity or decreased phenytoin levels have been reported in patients receiving phenytoin concomitantly with Welchol (colesevelam HCl)

-- Reduced International Normalized Ratio (INR) has been reported in patients receiving warfarin concomitantly with Welchol

-- Elevated thyroid-stimulating hormone (TSH) has been reported in patients receiving thyroid hormone replacement therapy

Pregnancy

Welchol is Pregnancy Category B

About Welchol (colesevelam HCl)

Welchol, along with diet and exercise, lowers LDL or "bad" cholesterol. It can be taken alone or with other cholesterol-lowering medications known as statins. Welchol, along with diet and exercise, also lowers blood sugar levels in adult patients with type 2 diabetes mellitus when added to other anti-diabetic medications (metformin, sulfonylureas, or insulin). Welchol was approved by the FDA to lower bad cholesterol in 2000 and to lower blood sugar levels in 2008. Welchol is available in two formulations, Welchol tablets and Welchol® for Oral Suspension.

Welchol should not be used to treat type 1 diabetes or diabetic ketoacidosis, and it has not been studied with all anti-diabetic medications. Welchol is not for everyone, especially those with a history of intestinal blockage, those with blood triglyceride levels of greater than 500 mg/dL, or a history of pancreatitis (inflammation of the pancreas) due to high triglyceride levels.

In clinical studies of adult patients with type 2 diabetes, Welchol lowered A1C, fasting blood sugar and LDL-C, important risk factors for heart disease. In clinical studies of patients with elevated LDL-C, Welchol lowered LDL-C when used alone or when added to other cholesterol-lowering medications known as statins. Welchol has not been shown to prevent heart disease or heart attacks.

References

1. Cheung BMY et al. Diabetes Prevalence and Therapeutic Target Achievement in the United States, 1999 to 2006. The American Journal of Medicine. 2009;122:443-453.

2. Center for Disease Control, National Diabetes Fact Sheet 2007.

3. American Diabetes Association. I Decide to Fight Diabetes Fact Sheet.

4. Brunzell JD, Davidson M, Furberg CD, et al. Lipoprotein Management in Patients with Cardiometabolic Risk: Consensus Statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care. 2008;31(4):811-822.

5. Buse JB, Ginsberg HN, Bakris GL, et al. Primary Prevention of Cardiovascular Diseases in People With Diabetes Mellitus: A Scientific Statement From the American Heart Association and the American Diabetes Association. Circulation.

6. American Diabetes Association: Standards of Medical Care in Diabetes - 2010. Diabetes Care. 2010; 33 (Suppl 1): S11-S61

Source: Daiichi Sankyo

Please rate this article:
(Hover over the stars
then click to rate) Bookmark and Share

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.

All opinions are moderated before being added.

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:






View the original article here